Andrew H. Gesek is a senior executive with over three decades of leadership across pharmaceuticals, medical devices, life sciences, and entrepreneurial ventures. His career reflects a consistent dedication to shaping organizations through strategic foresight, commercial acumen, and the ability to bridge the gap between traditional business models and emerging technologies. With experience spanning from global pharmaceutical giants to small business ownership, Andy has cultivated a unique leadership profile that blends operational discipline with visionary innovation.
From the early stages of his career, Andy demonstrated a natural ability to manage complexity and lead cross-functional teams. After earning his Bachelor of Science in Accounting and Finance from Drexel University in 1993, he entered the pharmaceutical sector, taking on finance and sales roles at Janssen, Novartis, and Pharmacia. These formative experiences gave him a deep understanding of the industry’s financial and operational dynamics, while also honing his analytical skills and ability to guide strategic decision-making. His early success in identifying profitable opportunities and redesigning budget processes set the foundation for his ascent into more senior leadership roles.
Andy’s career trajectory accelerated at Wyeth Pharmaceuticals, where he was appointed Executive Director of Global Forecasting. Here, he was responsible for overseeing $18 billion in revenues, ensuring accurate forecasting, and advising executive leadership on risks and opportunities in both U.S. and international markets. He introduced innovative approaches to scenario planning and negotiated with generic competitors to protect a $3 billion franchise, a testament to his ability to safeguard value while navigating the pressures of a competitive and evolving marketplace. His leadership transformed forecasting from a transactional activity into a strategic driver of corporate performance.
At Endo Pharmaceuticals, Andy took on a series of increasingly complex roles, culminating in his position as Vice President of Business Operations & Strategy and General Manager of Established Products. Managing a $450 million revenue unit with $400 million EBIT, Andy spearheaded growth initiatives that drove $250 million in net sales over five years. He also orchestrated acquisitions such as Sumavel DosePro and Natesto, while developing an outsourced support model that cut costs by 75% during a major headcount reduction. His ability to align financial rigor with commercial strategy positioned Endo for sustained competitiveness, while his focus on technology-pharma integration positioned the company at the forefront of industry innovation.
Building upon this record of accomplishment, Andy transitioned into entrepreneurial leadership as President of Timm Medical Technologies. Under his stewardship, the company was transformed from a struggling unit into a thriving, profitable enterprise. Through disciplined strategic planning and a relentless focus on operational improvement, Andy converted a $1 million annual loss into $6.5 million in revenue and $1.6 million EBITDA within three years. This turnaround culminated in a successful exit that delivered a six-fold return to investors. Andy’s tenure at Timm Medical highlights his capacity not only to grow businesses but also to inspire confidence among stakeholders through transparent leadership and sustainable value creation.
Since 2022, Andy has served as a Commercial and Strategy Consultant with Neuraptive Therapeutics, a development-stage biopharmaceutical company. In this role, he has advised leadership teams on commercial forecasting, narrative development for capital raising, and the pursuit of strategic business development opportunities. His efforts have contributed directly to investor confidence and positioned Neuraptive for growth through targeted technology licensing. This work underscores Andy’s adaptability in applying his expertise to organizations at different stages of maturity, from startups seeking capital to established enterprises navigating market challenges.
Parallel to his consulting practice, Andy has engaged in entrepreneurial ventures through ownership roles in companies such as Holy Land Wood and Stone and Street Level Sales. These endeavors reflect his passion for small business innovation and his commitment to supporting enterprises outside the life sciences sector. His diverse portfolio of experiences demonstrates both versatility and a willingness to embrace new challenges, always with the same discipline and strategic clarity that has defined his corporate career.
Andy’s academic journey also played a critical role in shaping his leadership ethos. In 2001, he completed the Executive MBA program at The Wharton School of the University of Pennsylvania, one of the world’s premier business institutions. His education equipped him with a strong foundation in strategic planning, finance, and global leadership, complementing his real-world experience and enabling him to thrive in complex, high-stakes environments.
Beyond his professional achievements, Andy is deeply committed to personal growth, mentorship, and community engagement. He is passionate about fostering innovation within organizations while guiding the next generation of leaders. A dedicated sports enthusiast and family man, he draws energy from basketball, time at the beach, and quality moments with loved ones. These personal passions bring balance to his professional pursuits, reinforcing his belief that strong leadership is rooted in authenticity, resilience, and perspective.
Today, Andy stands as a seasoned executive whose career represents a balance of strategic insight, operational excellence, and a passion for building sustainable success. With 30 years of diverse experience, he is poised to bring value to boards, advisory committees, and executive teams that seek transformative growth, industry foresight, and the ability to innovate responsibly in dynamic markets. His leadership journey embodies not only measurable business results but also the values of integrity, collaboration, and long-term vision.
Character:
Andy exemplifies integrity, resilience, and an unwavering commitment to doing what is right for both organizations and people. His leadership style is marked by humility and authenticity, creating trust across all levels of an organization. He believes that strong character is the cornerstone of lasting influence.
Knowledge:
With three decades of experience across pharmaceuticals, medical devices, life sciences, and small business leadership, Andy brings unparalleled expertise to the table. His education at Wharton and Drexel, combined with real-world achievements, equips him with both academic rigor and practical insight. He is deeply knowledgeable in strategic planning, financial modeling, business development, and innovation.
Strategic:
Andy is a proven strategist who consistently aligns vision with execution, guiding organizations through growth, transformation, and uncertainty. He has driven billion-dollar portfolios, executed successful acquisitions, and scaled small businesses into profitable ventures. His ability to see the big picture while navigating details ensures that strategy is always actionable and results-driven.
Communication:
As an executive, Andy is adept at communicating complex strategies in a clear, compelling, and collaborative way. Whether presenting to investors, negotiating with partners, or mentoring teams, he ensures alignment and shared purpose. His open and transparent communication style has been instrumental in building high-performance teams and inspiring organizational confidence.
